Oncology Market by Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, Others); by Therapeutic Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Others); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Industry Trends, Price Trends, Growth, Size, Supply, Demand, Comparative Analysis, Competitive Market Share and Forecast, 2018-2026

Report ID :AMI-12 | Category : Healthcare | Published Date :March, 2018 | Pages : 222 | Format :PDF
Buy Now!

Industry Trends

Oncology is a study of Cancer. The illness is described by irregular cell multiplication, which is trailed by local tissue invasion. At an advanced stage of the disease, the cancer cells migrate to different parts of the body. Cancer is a hereditarily determined illness, with iterative transformations giving selective advantages to the cells with regards to the particular tissue site, trailed by clonal expansion. The oncology market, in terms of revenue, was valued at USD 93.60 Bn in 2016 and is expected to reach US$ 127.52 Bn by 2021.

Global Oncology Market (USD Billion), By Region, 2018 - 2026 

Oncology Industry

Cancer is foreseen to become increasingly prevalent because of aging population and rising levels of obesity in the developed world. Besides, the advancement and approval of more targeted oncology treatments are foreseen to decrease toxicity and increase chemotherapy use in elderly patients. Targeted treatment organization will upturn the overall survival.

In 2012, there were 32.6 million individuals living with cancer within five years of diagnosis. These are generally incurable once they advance to the phase where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of numerous kinds, at different illness stages. In a typical course of treatment for cancer, numerous chemotherapy compounds are regulated consecutively in combination regimens, as an adjunct to surgery and radiation treatment. Chemotherapy drugs are cytotoxic to partitioning cells, implying that they follow up on both healthy and malignant tissues and are fairly lethal.

Various common etiologic variables have been emphatically portrayed as raising the risk of developing cancer, including age, interminable irritation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases exceedingly in patients beyond 65 years old. Populations in developed countries are anticipated to become progressively aged and demonstrate rising obesity incidence, which will drive both cancer predominance and revenue growth for its treatments.

Oncology Market, By Cancer Type

On the basis of cancer type, the global market is segmented into blood cancer, breast cancer, prostate cancer, skin cancer, and lung cancer among others. Among these, blood cancer segment represented a major share of the global oncology market in 2016 and is anticipated to hold the largest share of the overall market throughout the forecast period. The development of blood cancer segment is significant because of the high cost of the medications used to treat blood cancer. The prevalence of blood cancer is less in well-established countries, and also diagnosis rate is over 90%. This results in most of the individuals diagnosed striving for complete treatment to cure it. Because of the high disposable incomes of customers in developed nations, costly medication treatment of blood cancer is affordable in these regions.

Oncology Market, By Region

North America dominates the market for cancer drugs as the region houses organizations occupied with the advancement in cancer drugs. Correspondingly, the disposable revenues of consumers and health insurance cover for severe sickness in North America are high, which expands the affordability of tumor treatment. Furthermore, US Food and Drug Administration (USFDA) has undertaken activities to support the development of the market by giving a pre-market approval to the medications, which are in the clinical stage; in this way, accelerating the clinical development.

Countless patents in North America demonstrate a substantial investment in R&D from multinational organizations and also research organizations. Europe is the second largest revenue generating region for the oncology market and is relied upon to develop at a CAGR of 7.9% amid the forecast time frame. In U.S. and Europe, a majority of the multinational players has focused on the development of biologics or immunotherapeutic inferable from its high adequacy and target particular action. The research for cancer drugs in Asia-Pacific and LAMEA is rising with the concentration towards the improvement of biosimilars. The predominance of high growth in developing nations, renders these districts as promising areas to direct clinical trials. In addition, the cost of clinical research is low in these region, because of the availability of an enormous population base and good government arrangements adding to the oncology/malignancy drugs showcase development in the developing nations.

Competitive Landscape

The report provides both, qualitative and quantitative research of the market. The report also offers extensive research and detailed insight on the competitiveness of the key players in this market. The key business strategies such as M&A, affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin. Some of the primary players of global oncology market are Roche, Novartis, Celgene, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Eli Lilly, AstraZeneca, AbbVie, Incyte, Eisai, Sanofi and Merck & Co. among others.

Oncology Industry Background

Oncology Industry

Oncology Industry

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Oncology Market Snapshot

3.    Executive Summary: Oncology Market

4.    Qualitative Analysis: Oncology Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Oncology Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

5.2.1.   Chemotherapy

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   Targeted therapy

5.2.2.1.    Definition

5.2.2.2.    Market Penetration

5.2.2.3.    Market Revenue Expected to Increase by 2026

5.2.2.4.    Compound Annual Growth Rate (CAGR)

5.2.3.   Immunotherapy

5.2.3.1.    Definition

5.2.3.2.    Market Penetration

5.2.3.3.    Market Revenue Expected to Increase by 2026

5.2.3.4.    Compound Annual Growth Rate (CAGR)

5.2.4.   Hormonal therapy

5.2.4.1.    Definition

5.2.4.2.    Market Penetration

5.2.4.3.    Market Revenue Expected to Increase by 2026

5.2.4.4.    Compound Annual Growth Rate (CAGR)

5.2.5.   Radiation therapy

5.2.5.1.    Definition

5.2.5.2.    Market Penetration

5.2.5.3.    Market Revenue Expected to Increase by 2026

5.2.5.4.    Compound Annual Growth Rate (CAGR)

5.2.6.   Others

5.2.6.1.    Definition

5.2.6.2.    Market Penetration

5.2.6.3.    Market Revenue Expected to Increase by 2026

5.2.6.4.    Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Therapeutic Treatment

6.    Global Oncology Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

6.2.1.   Blood cancer

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Breast cancer

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.2.3.   Prostate cancer

6.2.3.1.    Definition

6.2.3.2.    Market Penetration

6.2.3.3.    Market Revenue Expected to Increase by 2026

6.2.3.4.    Compound Annual Growth Rate (CAGR)

6.2.4.   Skin cancer

6.2.4.1.    Definition

6.2.4.2.    Market Penetration

6.2.4.3.    Market Revenue Expected to Increase by 2026

6.2.4.4.    Compound Annual Growth Rate (CAGR)

6.2.5.   Lung cancer

6.2.5.1.    Definition

6.2.5.2.    Market Penetration

6.2.5.3.    Market Revenue Expected to Increase by 2026

6.2.5.4.    Compound Annual Growth Rate (CAGR)

6.2.6.   Other cancers

6.2.6.1.    Definition

6.2.6.2.    Market Penetration

6.2.6.3.    Market Revenue Expected to Increase by 2026

6.2.6.4.    Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Cancer Types

7.    North America Oncology Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Market Revenue (US$ Mn)

7.2.   North America Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

7.2.1.   Chemotherapy

7.2.2.   Targeted therapy

7.2.3.   Immunotherapy

7.2.4.   Hormonal therapy

7.2.5.   Radiation therapy

7.2.6.   Others

7.3.   North America Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

7.3.1.   Blood cancer

7.3.2.   Breast cancer

7.3.3.   Prostate cancer

7.3.4.   Skin cancer

7.3.5.   Lung cancer

7.3.6.   Other cancers

7.4.   North America Oncology Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1. U.S. Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

7.4.1.1.1.    Chemotherapy

7.4.1.1.2.    Targeted therapy

7.4.1.1.3.    Immunotherapy

7.4.1.1.4.    Hormonal therapy

7.4.1.1.5.    Radiation therapy

7.4.1.1.6.    Others

7.4.1.2.    U.S. Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

7.4.1.2.1.    Blood cancer

7.4.1.2.2.    Breast cancer

7.4.1.2.3.    Prostate cancer

7.4.1.2.4.    Skin cancer

7.4.1.2.5.    Lung cancer

7.4.1.2.6.    Other cancers

7.4.2.   Rest of North America

7.4.2.1.  Rest of North America Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

7.4.2.1.1.    Chemotherapy

7.4.2.1.2.    Targeted therapy

7.4.2.1.3.    Immunotherapy

7.4.2.1.4.    Hormonal therapy

7.4.2.1.5.    Radiation therapy

7.4.2.1.6.    Others

7.4.2.2.  Rest of North America Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

7.4.2.2.1.    Blood cancer

7.4.2.2.2.    Breast cancer

7.4.2.2.3.    Prostate cancer

7.4.2.2.4.    Skin cancer

7.4.2.2.5.    Lung cancer

7.4.2.2.6.    Other cancers

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Therapeutic Treatment

7.5.3.   By Cancer Types

8.    Europe Oncology Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.2.1.   Chemotherapy

8.2.2.   Targeted therapy

8.2.3.   Immunotherapy

8.2.4.   Hormonal therapy

8.2.5.   Radiation therapy

8.2.6.   Others

8.3.   Europe Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.3.1.   Blood cancer

8.3.2.   Breast cancer

8.3.3.   Prostate cancer

8.3.4.   Skin cancer

8.3.5.   Lung cancer

8.3.6.   Other cancers

8.4.   Europe Oncology Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.  France Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.1.1.1.    Chemotherapy

8.4.1.1.2.    Targeted therapy

8.4.1.1.3.    Immunotherapy

8.4.1.1.4.    Hormonal therapy

8.4.1.1.5.    Radiation therapy

8.4.1.1.6.    Others

8.4.1.2.    France Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.1.2.1.    Blood cancer

8.4.1.2.2.    Breast cancer

8.4.1.2.3.    Prostate cancer

8.4.1.2.4.    Skin cancer

8.4.1.2.5.    Lung cancer

8.4.1.2.6.    Other cancers

8.4.2.   The UK

8.4.2.1.  The UK Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.2.1.1.    Chemotherapy

8.4.2.1.2.    Targeted therapy

8.4.2.1.3.    Immunotherapy

8.4.2.1.4.    Hormonal therapy

8.4.2.1.5.    Radiation therapy

8.4.2.1.6.    Others

8.4.2.2.    The UK Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.2.2.1.    Blood cancer

8.4.2.2.2.    Breast cancer

8.4.2.2.3.    Prostate cancer

8.4.2.2.4.    Skin cancer

8.4.2.2.5.    Lung cancer

8.4.2.2.6.    Other cancers

8.4.3.   Spain

8.4.3.1. Spain Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.3.1.1.    Chemotherapy

8.4.3.1.2.    Targeted therapy

8.4.3.1.3.    Immunotherapy

8.4.3.1.4.    Hormonal therapy

8.4.3.1.5.    Radiation therapy

8.4.3.1.6.    Others

8.4.3.2.    Spain Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.3.2.1.    Blood cancer

8.4.3.2.2.    Breast cancer

8.4.3.2.3.    Prostate cancer

8.4.3.2.4.    Skin cancer

8.4.3.2.5.    Lung cancer

8.4.3.2.6.    Other cancers

8.4.4.   Germany

8.4.4.1.  Germany Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.4.1.1.    Chemotherapy

8.4.4.1.2.    Targeted therapy

8.4.4.1.3.    Immunotherapy

8.4.4.1.4.    Hormonal therapy

8.4.4.1.5.    Radiation therapy

8.4.4.1.6.    Others

8.4.4.2.    Germany Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.4.2.1.    Blood cancer

8.4.4.2.2.    Breast cancer

8.4.4.2.3.    Prostate cancer

8.4.4.2.4.    Skin cancer

8.4.4.2.5.    Lung cancer

8.4.4.2.6.    Other cancers

8.4.5.   Italy

8.4.5.1. Italy Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.5.1.1.    Chemotherapy

8.4.5.1.2.    Targeted therapy

8.4.5.1.3.    Immunotherapy

8.4.5.1.4.    Hormonal therapy

8.4.5.1.5.    Radiation therapy

8.4.5.1.6.    Others

8.4.5.2.    Italy Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.5.2.1.    Blood cancer

8.4.5.2.2.    Breast cancer

8.4.5.2.3.    Prostate cancer

8.4.5.2.4.    Skin cancer

8.4.5.2.5.    Lung cancer

8.4.5.2.6.    Other cancers

8.4.6.   Rest of Europe

8.4.6.1.  Rest of Europe Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

8.4.6.1.1.    Chemotherapy

8.4.6.1.2.    Targeted therapy

8.4.6.1.3.    Immunotherapy

8.4.6.1.4.    Hormonal therapy

8.4.6.1.5.    Radiation therapy

8.4.6.1.6.    Others

8.4.6.2.    Rest of Europe Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

8.4.6.2.1.    Blood cancer

8.4.6.2.2.    Breast cancer

8.4.6.2.3.    Prostate cancer

8.4.6.2.4.    Skin cancer

8.4.6.2.5.    Lung cancer

8.4.6.2.6.    Other cancers

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Therapeutic Treatment

8.5.3.   By Cancer Types

9.    Asia Pacific  Oncology Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.2.1.   Chemotherapy

9.2.2.   Targeted therapy

9.2.3.   Immunotherapy

9.2.4.   Hormonal therapy

9.2.5.   Radiation therapy

9.2.6.   Others

9.3.   Asia Pacific Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.3.1.   Blood cancer

9.3.2.   Breast cancer

9.3.3.   Prostate cancer

9.3.4.   Skin cancer

9.3.5.   Lung cancer

9.3.6.   Other cancers

9.4.   Asia Pacific Oncology Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1. China Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.4.1.1.1.    Chemotherapy

9.4.1.1.2.    Targeted therapy

9.4.1.1.3.    Immunotherapy

9.4.1.1.4.    Hormonal therapy

9.4.1.1.5.    Radiation therapy

9.4.1.1.6.    Others

9.4.1.2.    China Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.4.1.2.1.    Blood cancer

9.4.1.2.2.    Breast cancer

9.4.1.2.3.    Prostate cancer

9.4.1.2.4.    Skin cancer

9.4.1.2.5.    Lung cancer

9.4.1.2.6.    Other cancers

9.4.2.   Japan

9.4.2.1. Japan Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.4.2.1.1.    Chemotherapy

9.4.2.1.2.    Targeted therapy

9.4.2.1.3.    Immunotherapy

9.4.2.1.4.    Hormonal therapy

9.4.2.1.5.    Radiation therapy

9.4.2.1.6.    Others

9.4.2.2.    Japan Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.4.2.2.1.    Blood cancer

9.4.2.2.2.    Breast cancer

9.4.2.2.3.    Prostate cancer

9.4.2.2.4.    Skin cancer

9.4.2.2.5.    Lung cancer

9.4.2.2.6.    Other cancers

9.4.3.   India

9.4.3.1. India Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.4.3.1.1.    Chemotherapy

9.4.3.1.2.    Targeted therapy

9.4.3.1.3.    Immunotherapy

9.4.3.1.4.    Hormonal therapy

9.4.3.1.5.    Radiation therapy

9.4.3.1.6.    Others

9.4.3.2.    India Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.4.3.2.1.    Blood cancer

9.4.3.2.2.    Breast cancer

9.4.3.2.3.    Prostate cancer

9.4.3.2.4.    Skin cancer

9.4.3.2.5.    Lung cancer

9.4.3.2.6.    Other cancers

9.4.4.   Southeast Asia

9.4.4.1. Southeast Asia Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.4.4.1.1.    Chemotherapy

9.4.4.1.2.    Targeted therapy

9.4.4.1.3.    Immunotherapy

9.4.4.1.4.    Hormonal therapy

9.4.4.1.5.    Radiation therapy

9.4.4.1.6.    Others

9.4.4.2.  Southeast Asia Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.4.4.2.1.    Blood cancer

9.4.4.2.2.    Breast cancer

9.4.4.2.3.    Prostate cancer

9.4.4.2.4.    Skin cancer

9.4.4.2.5.    Lung cancer

9.4.4.2.6.    Other cancers

9.4.5.   Rest of Asia Pacific

9.4.5.1. Rest of Asia Pacific Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

9.4.5.1.1.    Chemotherapy

9.4.5.1.2.    Targeted therapy

9.4.5.1.3.    Immunotherapy

9.4.5.1.4.    Hormonal therapy

9.4.5.1.5.    Radiation therapy

9.4.5.1.6.    Others

9.4.5.2.  Rest of Asia Pacific Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

9.4.5.2.1.    Blood cancer

9.4.5.2.2.    Breast cancer

9.4.5.2.3.    Prostate cancer

9.4.5.2.4.    Skin cancer

9.4.5.2.5.    Lung cancer

9.4.5.2.6.    Other cancers

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Therapeutic Treatment

9.5.3.   By Cancer Types

10. Middle East and Africa  Oncology Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

10.2.1. Chemotherapy

10.2.2. Targeted therapy

10.2.3. Immunotherapy

10.2.4. Hormonal therapy

10.2.5. Radiation therapy

10.2.6. Others

10.3. Middle East and Africa Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

10.3.1. Blood cancer

10.3.2. Breast cancer

10.3.3. Prostate cancer

10.3.4. Skin cancer

10.3.5. Lung cancer

10.3.6. Other cancers

10.4. Middle East and Africa Oncology Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1. GCC Countries Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

10.4.1.1.1.  Chemotherapy

10.4.1.1.2.  Targeted therapy

10.4.1.1.3.  Immunotherapy

10.4.1.1.4.  Hormonal therapy

10.4.1.1.5.  Radiation therapy

10.4.1.1.6.  Others

10.4.1.2.  GCC Countries Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

10.4.1.2.1.  Blood cancer

10.4.1.2.2.  Breast cancer

10.4.1.2.3.  Prostate cancer

10.4.1.2.4.  Skin cancer

10.4.1.2.5.  Lung cancer

10.4.1.2.6.  Other cancers

10.4.2. Southern Africa

10.4.2.1. Southern Africa Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

10.4.2.1.1.  Chemotherapy

10.4.2.1.2.  Targeted therapy

10.4.2.1.3.  Immunotherapy

10.4.2.1.4.  Hormonal therapy

10.4.2.1.5.  Radiation therapy

10.4.2.1.6.  Others

10.4.2.2.  Southern Africa Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

10.4.2.2.1.  Blood cancer

10.4.2.2.2.  Breast cancer

10.4.2.2.3.  Prostate cancer

10.4.2.2.4.  Skin cancer

10.4.2.2.5.  Lung cancer

10.4.2.2.6.  Other cancers

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

10.4.3.1.1.  Chemotherapy

10.4.3.1.2.  Targeted therapy

10.4.3.1.3.  Immunotherapy

10.4.3.1.4.  Hormonal therapy

10.4.3.1.5.  Radiation therapy

10.4.3.1.6.  Others

10.4.3.2.  Rest of MEA Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

10.4.3.2.1.  Blood cancer

10.4.3.2.2.  Breast cancer

10.4.3.2.3.  Prostate cancer

10.4.3.2.4.  Skin cancer

10.4.3.2.5.  Lung cancer

10.4.3.2.6.  Other cancers

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Therapeutic Treatment

10.5.3. By Cancer Types

11. Latin America Oncology Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

11.2.1. Chemotherapy

11.2.2. Targeted therapy

11.2.3. Immunotherapy

11.2.4. Hormonal therapy

11.2.5. Radiation therapy

11.2.6. Others

11.3. Latin America Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

11.3.1. Blood cancer

11.3.2. Breast cancer

11.3.3. Prostate cancer

11.3.4. Skin cancer

11.3.5. Lung cancer

11.3.6. Other cancers

11.4. Latin America Oncology Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1. Brazil Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

11.4.1.1.1.  Chemotherapy

11.4.1.1.2.  Targeted therapy

11.4.1.1.3.  Immunotherapy

11.4.1.1.4.  Hormonal therapy

11.4.1.1.5.  Radiation therapy

11.4.1.1.6.  Others

11.4.1.2.  Brazil Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

11.4.1.2.1.  Blood cancer

11.4.1.2.2.  Breast cancer

11.4.1.2.3.  Prostate cancer

11.4.1.2.4.  Skin cancer

11.4.1.2.5.  Lung cancer

11.4.1.2.6.  Other cancers

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Oncology Market Revenue (US$ Mn) and Forecasts, By Therapeutic Treatment

11.4.2.1.1.  Chemotherapy

11.4.2.1.2.  Targeted therapy

11.4.2.1.3.  Immunotherapy

11.4.2.1.4.  Hormonal therapy

11.4.2.1.5.  Radiation therapy

11.4.2.1.6.  Others

11.4.2.2.  Rest of Latin America Oncology Market Revenue (US$ Mn) and Forecasts, By Cancer Types

11.4.2.2.1.  Blood cancer

11.4.2.2.2.  Breast cancer

11.4.2.2.3.  Prostate cancer

11.4.2.2.4.  Skin cancer

11.4.2.2.5.  Lung cancer

11.4.2.2.6.  Other cancers

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Therapeutic Treatment

11.5.3. By Cancer Types

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. AbbVie Inc.

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. AstraZeneca

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Bristol-Myers Squibb Company

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. CELGENE CORPORATION

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. Eli Lilly and Company

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. F. Hoffmann-La Roche Ltd.

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Johnson & Johnson Services, Inc.

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

13.8. Merck & Co., Inc.

13.8.1. Company Details

13.8.2. Company Overview

13.8.3. Product Offerings

13.8.4. Key Developments

13.8.5. Financial Analysis

13.8.6. SWOT Analysis

13.8.7. Business Strategies

13.9. Novartis AG

13.9.1. Company Details

13.9.2. Company Overview

13.9.3. Product Offerings

13.9.4. Key Developments

13.9.5. Financial Analysis

13.9.6. SWOT Analysis

13.9.7. Business Strategies

13.10. Pfizer Inc.

13.10.1. Company Details

13.10.2. Company Overview

13.10.3. Product Offerings

13.10.4. Key Developments

13.10.5. Financial Analysis

13.10.6. SWOT Analysis

13.10.7. Business Strategies

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country  and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends. 

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once